Last reviewed · How we verify
NCT04921397: CASES-TCM
China Stroke Registry for Patients With Traditional Chinese Medicine
trial in Ischemic Stroke in 20,000 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Dongzhimen Hospital, Beijing |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20,000 |
| Start date | 11 June 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across China |
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Intracerebral Hemorrhage — all drugs for Intracerebral Hemorrhage →
Sponsor
Dongzhimen Hospital, Beijing
Who can join
18 and older, any sex, with Ischemic Stroke or Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The CASES-TCM study is a prospective, multicenter, observational study, which will enroll 20,000 patients with acute stroke (ischemic stroke or intracerebral hemorrhage) within 7 days of symptom onset. This study attempts to depict major clinical characteristics of acute stroke in patients with Chinese medicine treatment and to explore any difference compared with other non-Chinese medicine use cohorts and the effectiveness and safety of Chinese medicine.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
China Stroke Registry for Patients With Traditional Chinese Medicine (CASES-TCM): Rationale and Design of a Prospective, Multicenter, Observational Study.
Feng L, Kong L, Dong X, Lai X, et al · · 2021 · cited 8× · PMID 34531755 · DOI 10.3389/fphar.2021.743883
Verify or expand the search:
- PubMed search for NCT04921397
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Dongzhimen Hospital, Beijing trials
Trials by the same sponsor.
- NCT07271732 — Songling Xuemaikang Capsules for Cerebral Small Vessel Disease · NA · not yet recruiting
- NCT07342075 — Registry Study of Cerebral Small Vessel Disease · recruiting
- NCT07163702 — Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke · Phase 2 · not yet recruiting
- NCT06857487 — Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke · Phase 1, PHASE2 · recruiting
- NCT06933238 — Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04921397 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dongzhimen Hospital, Beijing
- Last refreshed: 10 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04921397.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing